FDA Grants Fast Track Status to Invikafusp Alfa
The drug is now being fast-tracked for TMB-H solid tumors, potentially speeding development for patients with this biomarker.
Updated on Oct. 15, 2026 in Cancer
The FDA has granted Fast Track status to the investigational drug invikafusp alfa for the treatment of solid tumors characterized as tumor mutational burden-high (TMB-H). This regulatory designation is designed to accelerate the development of new therapies for serious conditions with unmet medical needs.
Why it matters
TMB-H tumors, defined by having at least 10 mutations per megabase, represent a specific genetic profile that may respond to immune-targeted therapies. This designation reflects an ongoing effort to broaden access to investigational treatments for patients whose cancers share this biomarker regardless of where the tumor originated.
The FDA designation recognizes invikafusp alfa for TMB-H solid tumors, which are clinically defined by at least 10 mutations per megabase. Clinical efficacy and safety profiles for the drug remain under investigation as it has not yet received approval from any regulatory authority.
The players
Food and Drug Administration
The federal agency responsible for regulating pharmaceuticals and public health in the United States.
The details
Invikafusp alfa is an investigational bispecific dual T-cell agonist designed to activate the immune system against cancer cells. The molecule functions by targeting Vbeta6 and Vbeta10 T-cell receptor regions while simultaneously delivering a co-stimulatory signal. This dual action encourages the expansion of effector memory T cells, which are specialized immune cells that can identify and attack tumor cells.
Timeline
January 2025: Invikafusp alfa received its first Fast Track designation for colorectal cancer.
October 15, 2026: The FDA granted expanded Fast Track status to include all TMB-H solid tumors.
October 23, 2026: Updated phase 2 results were presented at the ESMO Congress in Madrid.
Health Landscape
The development of invikafusp alfa aligns with the broader medical shift toward biomarker-driven oncology, where treatments are matched to genetic profiles rather than just tumor location. This approach builds upon the foundational precedent set by the 2020 FDA accelerated approval of pembrolizumab for TMB-H tumors.
Patients with advanced solid tumors should ask their oncologist whether tumor genomic profiling has been performed to identify a TMB-H status. Understanding your tumor's genetic profile is a conversation worth having with your physician to discuss all potential treatment or trial options.
The takeaway
The FDA's Fast Track designation highlights the growing clinical focus on TMB-H as a targetable genetic biomarker across diverse cancer types. Patients should consult their care team about whether their tumor profile qualifies for trials or future therapies focusing on this specific mutation threshold.
Further reading
For more on evolving treatment approaches, see our Cancer section.
